In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.

Journal article

INTRODUCTION: Trastuzumab, a humanized antibody directed against the Her2 receptor, induces the expression of p27(kip1), an intranuclear cyclin-dependent kinase inhibitor in some breast cancer cells. The aim of this study was to develop a radioimmunoconjugate (RIC) to monitor trastuzumab-induced p27(kip1) protein up-regulation in vivo. MATERIALS AND METHODS: Anti-p27(kip1) IgG was purified, and conjugated to diethylenetriaminopentaacetate, to allow radiolabeling with (111)In for in vivo detec...

Expand abstract

Authors: Cornelissen, B; Kersemans, V; McLarty, K; Tran, L; Vallis, K

• Publication status: Published
• Journal: Nuclear medicine and biology
• Volume: 36
• Issue: 7
• Pages: 811-819
• Publication date: 2009-10-01
• DOI: 10.1016/j.nucmedbio.2009.05.003
• EISSN: 1872-9614
• ISSN: 0969-8051
• Language: English
• Keywords: Animals; Antibodies, Monoclonal; Peptides; Antibodies, Monoclonal, Humanized; Cyclin-Dependent Kinase Inhibitor p27; Molecular Sequence Data; Cell Line, Tumor; Tissue Distribution; Immunoconjugates; Protein Transport; Gene Expression Regulation, Neoplastic; Up-Regulation; Pentetic Acid; Breast Neoplasms; Amino Acid Sequence; Mice; Time Factors; Treatment Outcome; Intranuclear Space; Cell Transformation, Neoplastic; Isotope Labeling; Humans